Audax Medical was granted an exclusive worldwide license from Northeastern University (NU) for a self-assembling, arginine-rich nanomolecule for development in tissue regeneration.
The nanomolecule was developed in Dr. Thomas Webster’s Nanomedicine Lab in NU’s Department of Chemical Engineering. Initial tests indicate the potential to accelerate healing and promote targeted cell functions, while limiting inflammation and infection. Notably, the nanoparticles inhibit bacteria without the use of antibiotics.
Audax seeks to develop the technology for applications in orthopaedics, spine, wound care, etc. In 2010, the company acquired exclusive rights to Arxis osteobiologic nanotechnology, under development for regeneration of bone, cartilage and other soft tissues.
Audax Medical was granted an exclusive worldwide license from Northeastern University (NU) for a self-assembling, arginine-rich nanomolecule for development in tissue regeneration.
The nanomolecule was developed in Dr. Thomas Webster's Nanomedicine Lab in NU's Department of Chemical Engineering. Initial tests indicate the potential to...
Audax Medical was granted an exclusive worldwide license from Northeastern University (NU) for a self-assembling, arginine-rich nanomolecule for development in tissue regeneration.
The nanomolecule was developed in Dr. Thomas Webster’s Nanomedicine Lab in NU’s Department of Chemical Engineering. Initial tests indicate the potential to accelerate healing and promote targeted cell functions, while limiting inflammation and infection. Notably, the nanoparticles inhibit bacteria without the use of antibiotics.
Audax seeks to develop the technology for applications in orthopaedics, spine, wound care, etc. In 2010, the company acquired exclusive rights to Arxis osteobiologic nanotechnology, under development for regeneration of bone, cartilage and other soft tissues.
Copy to clipboard 
